Abstract
Investigations into the role of heat shock proteins (HSPs) in immune response have progressed well into a third decade, and indications of their use for the treatment of renal cell carcinoma (RCC) in the adjuvant setting will be revealed in the near future when a randomized phase III clinical trial is completed. Additional ongoing and planned randomized clinical trials will test the efficacy of HSP-based vaccines in more advanced stages of RCC. This review describes the compelling scientific rationale behind testing HSPs in RCC against the backdrop of other immunotherapeutic approaches in this indication.
Original language | English (US) |
---|---|
Pages (from-to) | 425-433 |
Number of pages | 9 |
Journal | Urologic Oncology: Seminars and Original Investigations |
Volume | 24 |
Issue number | 5 |
DOIs | |
State | Published - Sep 2006 |
Keywords
- Autologous
- Heat shock protein
- Renal cell carcinoma
ASJC Scopus subject areas
- Oncology
- Urology